巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Angion Biomedica Corp

    ANGN
    0.939
    0.060
    6.12%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Angion Biomedica Corp - 延遲價格・最後更新於 26/09 12:00
    最高位
    1.000
    最低位
    0.939
    開市價
    --
    前收市價
    1.000
    成交量(千)
    0.42
    成交額(百萬)
    0.00
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    28.27
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    10.570 - 0.910
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Angion Biomedica Corp
    證券代碼
    ANGN.US
    所屬板塊
    Biotechnology
    公司業務
    Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
    發行量
    29958064
    公司總部
    51 Charles Lindbergh Boulevard
    公司網址
    https://www.angion.com
    公司電話
    +1 415 655-4899
    暫無內容

    關於

    Angion Biomedica Corp(ANGN.US)所屬的行業板塊為Biotechnology。
    Angion Biomedica Corp is a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading with ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
    詳細公司背景可參考: https://www.angion.com